Document is current
Any future updates will be listed below
-
Authors
Latzer, Pauline https://orcid.org/0000-0003-0479-084X
Zelba, Henning
Battke, Florian https://orcid.org/0000-0001-6021-5837
Reinhardt, Annekathrin
Shao, Borong
Bartsch, Oliver
Rabsteyn, Armin
Harter, Johannes
Schulze, Martin
Okech, Thomas
Golf, Alexander
Kyzirakos-Feger, Christina
Kayser, Simone
Pieper, Natalia
Feldhahn, Magdalena
Wünsche, Julian
Seitz, Christian
Hadaschik, Dirk
Garbe, Claus
Hauser, Till-Karsten https://orcid.org/0000-0001-7604-3419
la Fougère, Christian https://orcid.org/0000-0001-7519-0417
Biskup, Dirk
Brooke, Dawn
Parker, David
Martens, Uwe M. https://orcid.org/0000-0001-7999-4359
Illerhaus, Gerald
Blumenthal, Deborah T. https://orcid.org/0000-0002-8868-0148
Merrell, Ryan
Lorenzo, Luisa Sánchez
Hidvégi, Máté https://orcid.org/0000-0003-1616-0829
de Robles, Paula
Kebir, Sied
Li, William W.
Li, Vincent W.
Williams, Matthew
Miller, Alexandra M.
Kesari, Santosh https://orcid.org/0000-0003-3772-6000
Castro, Michael
Desjardins, Annick https://orcid.org/0000-0003-3869-8283
Ashley, David M. https://orcid.org/0000-0002-4754-5900
Friedman, Henry S. https://orcid.org/0000-0001-7588-032X
Wen, Patrick Y.
Neil, Elisabeth C.
Iwamoto, Fabio M.
Sipos, Bence https://orcid.org/0000-0002-7311-3343
Geletneky, Karsten
Zender, Lars https://orcid.org/0000-0001-7626-2849
Glas, Martin
Reardon, David A. https://orcid.org/0000-0001-6674-0157
Biskup, Saskia https://orcid.org/0000-0002-1573-861X
- License Information
-
More Information
Article History
Received: 29 February 2024
Accepted: 6 August 2024
First Online: 11 August 2024
Competing interests
: Disclosures for Patrick Y. Wen as research support: Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Celgene, Chimerix, Eli Lily, Erasca, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Servier, Vascular Biogenics, VBI Vaccines. Disclosures for Patrick Y. Wen as advisory board/consultant: Astra Zeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Insightec, Kintara, Merck, Mundipharma, Novartis, Novocure, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, VBI Vaccines. Conflict of interest for Uwe M. Martens as advisory role: BMS, MSD, Roche, Guardant Health, Sanofi-Aventis, GSK, Novartis. Conflict of interest for Uwe M. Martens as scientific support: Dieter Schwarz Foundation. Saskia Biskup and Dirk Biskup have ownership interests in CeCaVa GmbH and CeGaT GmbH. Dirk Hadaschik is an employee of CeCaVa GmbH. Florian Battke, Johannes Harter, and Magdalena Feldhahn are employed by CeGaT GmbH. Alexander Golf, Julian Wünsche, and Thomas Okech are employed by MVZ Zentrum für ambulante Onkologie GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. No competing interests were disclosed by the other authors.
